CT SB00262

Brand name drug manufacturers and wholesalers registered in Connecticut must make drugs distributed in the state available for sale to generic drug developers for testing required to support FDA applications.

Drugs must be sold to eligible product developers at a price not exceeding the wholesale acquisition cost (manufacturer's list price to wholesalers, excluding discounts or rebates) without restrictions that would block or delay generic applications.

Generic drug manufacturers receiving drugs at wholesale acquisition cost must charge Connecticut consumers the same price or less for their resulting generic products.

Brand name manufacturers and wholesalers are shielded from liability for injuries caused by the generic manufacturer's inadequate safety warnings or design defects, provided they complied with this requirement and did not manufacture the generic product.

Violations of the drug availability requirement or consumer pricing requirement are classified as unfair or deceptive trade practices under Connecticut law.

Act takes effect October 1, 2021.